- Home
- BMRC vs PROK Comparison
BMRC vs PROK Comparison
Compare BMRC & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMRC
- PROK
- Stock Information
- Founded
- BMRC 1989
- PROK 2015
- Country
- BMRC United States
- PROK United States
- Employees
- BMRC N/A
- PROK N/A
- Industry
- BMRC Major Banks
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BMRC Finance
- PROK Health Care
- Exchange
- BMRC Nasdaq
- PROK Nasdaq
- Market Cap
- BMRC 365.9M
- PROK 384.2M
- IPO Year
- BMRC N/A
- PROK N/A
- Fundamental
- Price
- BMRC $25.12
- PROK $2.16
- Analyst Decision
- BMRC Buy
- PROK Buy
- Analyst Count
- BMRC 4
- PROK 5
- Target Price
- BMRC $26.25
- PROK $6.25
- AVG Volume (30 Days)
- BMRC 83.8K
- PROK 1.7M
- Earning Date
- BMRC 10-27-2025
- PROK 08-12-2025
- Dividend Yield
- BMRC 4.06%
- PROK N/A
- EPS Growth
- BMRC N/A
- PROK N/A
- EPS
- BMRC 0.43
- PROK N/A
- Revenue
- BMRC $93,409,000.00
- PROK $527,000.00
- Revenue This Year
- BMRC $59.17
- PROK $265.05
- Revenue Next Year
- BMRC $15.96
- PROK N/A
- P/E Ratio
- BMRC $56.98
- PROK N/A
- Revenue Growth
- BMRC 59.35
- PROK N/A
- 52 Week Low
- BMRC $19.11
- PROK $0.46
- 52 Week High
- BMRC $27.11
- PROK $7.13
- Technical
- Relative Strength Index (RSI)
- BMRC 65.64
- PROK 41.37
- Support Level
- BMRC $23.86
- PROK $2.23
- Resistance Level
- BMRC $24.82
- PROK $2.44
- Average True Range (ATR)
- BMRC 0.53
- PROK 0.15
- MACD
- BMRC 0.16
- PROK -0.02
- Stochastic Oscillator
- BMRC 98.77
- PROK 4.76
About BMRC Bank of Marin Bancorp
Bank of Marin Bancorp is a United States-based bank holding company. It conducts business through its wholly-owned subsidiary. The Bank provides a wide range of financial services to customers such as professionals, small and middle-market businesses, and individuals residing in Marin, Sonoma, Napa, San Francisco, Alameda, Contra Costa, San Mateo counties and others. The majority of its revenue comes from interest income.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.